Neurogene (NGNE) Treasury Shares (2019 - 2026)
Neurogene (NGNE) reported Treasury Shares of $296578.0 for Q1 2026, up 17.63% on a YoY basis from $252124.0 in Q1 2025, and up 17.63% quarter-over-quarter from $252124.0 in Q4 2025.
Neurogene (NGNE) Treasury Shares (2019 - 2026) Analysis & Trends
Neurogene has reported Treasury Shares for 8 years, with the latest figure at $296578.0 in Q1 2026.
- For the quarter ending Q1 2026, Treasury Shares rose 17.63% year-over-year to $296578.0; the trailing twelve-month figure through Mar 2026 stood at $296578.0 (up 17.63% YoY), and the FY2025 full-year result was $252124.0, changed 0.0% from the prior year.
- Treasury Shares for Q1 2026 stood at $296578.0, up from $252124.0 in the prior quarter.
- The five-year high for Treasury Shares was $710000.0 in Q1 2022, with the low at $5750.0 in Q3 2023.
- Historically, Treasury Shares has averaged $305962.9 across 5 years, with a median of $264860.0 in 2025.
- Annual changes were most pronounced in 2023 — Treasury Shares plunged 98.73% — and 2024, when it soared 8206.31%.
- Neurogene's Treasury Shares stood at $6691.0 in 2022, then slipped by 14.06% to $5750.0 in 2023, then jumped by 4284.77% to $252124.0 in 2024, then changed by 0.0% to $252124.0 in 2025, then increased by 17.63% to $296578.0 in 2026.
- The last three Treasury Shares figures came in at $296578.0 (Q1 2026), $252124.0 (Q4 2025), and $257797.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 1.48 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 700,000.00 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Neurogene | 216.17 Mn | 216.17 Mn | - | 296,578.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 296,578.00 |
| Mar 31, 2026 | 296,578.00 |
| Dec 31, 2025 | 252,124.00 |
| Dec 31, 2025 | 252,124.00 |
| Sep 30, 2025 | 257,797.00 |
| Sep 30, 2025 | 257,797.00 |
| Jun 30, 2025 | 271,923.00 |
| Jun 30, 2025 | 271,923.00 |
| Mar 31, 2025 | 252,124.00 |
| Mar 31, 2025 | 252,124.00 |
| Dec 31, 2024 | 252,124.00 |
| Dec 31, 2024 | 252,124.00 |
| Sep 30, 2024 | 477,613.00 |
| Sep 30, 2024 | 477,613.00 |
| Jun 30, 2024 | 479,549.00 |
| Jun 30, 2024 | 479,549.00 |
| Mar 31, 2024 | 482,384.00 |
| Mar 31, 2024 | 482,384.00 |
| Sep 30, 2023 | 5,750.00 |
| Sep 30, 2023 | 5,750.00 |